Background: Despite multiple published studies reporting result of salvage regimens for
relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different …

Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …

Background: Chemotherapy with Adriamycin, Bleomycin, Vinblastine, and Dacarbazine
(ABVD regimen) cannot cure all patients with Hodgkin lymphoma. In this study, we …

6589 Background: Relapsed HD and NHL remain a therapeutic challenge. Non-cross
resistant therapy incorporating P is a standard approach, but the optimal regimen has not …

Objective: To determine the efficacy and toxicity of Gemcitabine, Vinorelbine and
Prednisolone (GVP) salvage chemotherapy in relapsed/refractory Hodgkin's Lymphoma …

The management of relapsed or refractory Hodgkin's lymphoma (RR-HL) remains a
challenge for hematologists and oncologists. Salvage chemotherapy followed by autologous …

Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However,
around 10% to 25% of patients will have primary refractory or relapsed disease, despite …

Hodgkin lymphoma (HL) is a relatively chemosensitive malignancy. However, for those who
relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of …

Background High-dose chemotherapy (HDT) followed by autologous stem-cell
transplantation (ASCT) is considered the gold standard in the treatment of patients with …

Background Salvage regimens in relapsed/refractory Hodgkin's lymphoma (HL) differ in their
efficacy and toxicity profiles. Gemcitabine (G), vinorelbine (V) and liposomal doxorubicin …